GWPRF - GW Pharmaceuticals plc

Other OTC - Other OTC Delayed Price. Currency in USD
13.66
+0.21 (+1.56%)
At close: 2:41PM EDT
Stock chart is not supported by your current browser
Previous Close13.45
Open13.61
Bid0.00 x 0
Ask0.00 x 0
Day's Range13.61 - 14.07
52 Week Range7.07 - 16.00
Volume2,542
Avg. Volume5,014
Market Cap5.035B
Beta (3Y Monthly)2.09
PE Ratio (TTM)N/A
EPS (TTM)-8.61
Earnings DateAug 5, 2019 - Aug 9, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Cramer goes off the charts to get a deeper look at cannabis stocks
    CNBC Videos2 months ago

    Cramer goes off the charts to get a deeper look at cannabis stocks

    Jim Cramer takes a look at his colleague and technician Tim Collins' interpretation of the cannabis sector.

  • Don't Hold Your Breath for the FDA's CBD Report
    Motley Fool2 days ago

    Don't Hold Your Breath for the FDA's CBD Report

    Despite promises of an expedited review, CBD-focused investors could be disappointed with the Food and Drug Administration's findings.

  • Here's Why Zogenix Leaped 26.8% in June
    Motley Fool13 days ago

    Here's Why Zogenix Leaped 26.8% in June

    The company rebounded after remedying an embarrassing regulatory gaffe.

  • Why Marijuana Stock GW Pharmaceuticals Soared 77% in the First Half of 2019
    Motley Fool14 days ago

    Why Marijuana Stock GW Pharmaceuticals Soared 77% in the First Half of 2019

    A hot cannabis sector and better-than-expected initial U.S. sales of its CBD-based drug, Epidiolex, lit a fire under this biotech's stock.

  • 5 Best Cannabis Stocks of 2019 So Far -- Are They Buys Now?
    Motley Fool18 days ago

    5 Best Cannabis Stocks of 2019 So Far -- Are They Buys Now?

    These cannabis stocks racked up gains of at least 60% in the first half of 2019. Which ones are most likely to keep the momentum going?

  • Better Buy: GW Pharmaceuticals vs. Cara Therapeutics
    Motley Fool19 days ago

    Better Buy: GW Pharmaceuticals vs. Cara Therapeutics

    Which one of these unconventional drugmakers can give your portfolio the biggest boost?

  • Why Medicare for all could 'dramatically' increase access to medical marijuana
    Yahoo Finance20 days ago

    Why Medicare for all could 'dramatically' increase access to medical marijuana

    Medicare for all may not be just a Democratic talking point as the 2020 campaign kicks into high gear. It could also “dramatically” increase access to medical marijuana, according to Nicholas Vita, CEO of cannabis company Columbia Care.

  • The Best Marijuana Stocks in the First Half of 2019
    Motley Fool20 days ago

    The Best Marijuana Stocks in the First Half of 2019

    Seven cannabis stocks doubled, and nearly two-thirds of all pot stocks ended the period higher.

  • Better Cannabis Stock: OrganiGram Holdings vs. GW Pharmaceuticals
    Motley Fool22 days ago

    Better Cannabis Stock: OrganiGram Holdings vs. GW Pharmaceuticals

    Which stock wins between this Canadian cannabis producer and leading cannabinoid-focused biotech?

  • The Surprising Pot Stock Forecast to Lead the Industry in 2020 Sales
    Motley Fool26 days ago

    The Surprising Pot Stock Forecast to Lead the Industry in 2020 Sales

    Hint: It's not Canopy Growth or Aurora Cannabis.

  • The Most Important Marijuana Growth Chart You'll Ever See
    Motley Fool28 days ago

    The Most Important Marijuana Growth Chart You'll Ever See

    A new report sheds light on where cannabis growth will come from in the years that lie ahead.

  • Motley Fool28 days ago

    Is CBD Bad for Your Liver? The Shocking Findings of 1 New Study

    Is the public's faith in cannabidiol misplaced?

  • Opinion: Medical Marijuana Is a Terrible Investment
    Motley Foollast month

    Opinion: Medical Marijuana Is a Terrible Investment

    Medical marijuana drug developers are often smothered in hype and rarely deliver any reward.

  • Is GW Pharmaceuticals plc (GWPH) A Good Stock To Buy?
    Insider Monkeylast month

    Is GW Pharmaceuticals plc (GWPH) A Good Stock To Buy?

    Before we spend countless hours researching a company, we'd like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]

  • 4 Hot Cannabis Stocks Growing Now
    TipRankslast month

    4 Hot Cannabis Stocks Growing Now

    It’s not often you get to witness the opening of a whole new market sector. After last year’s move by the Canadian Parliament to fully legalize marijuana and cannabis products throughout the country, and the increasing numbers of American states south of the border pursuing similar legalization policies, we are seeing just that. As Giadha Aquirre de Carcer, CEO of New Frontier Data, put it in a report on the worldwide cannabis market, “The legal cannabis industry has truly gone global; even in the face of extensive prohibition, cannabis consumption grows, and attitudes and challenging perceptions about the typical cannabis user continue to shift.”It’s an exciting time, one that is also opening new pathways for investment. In this article, we’ll dip into the TipRanks database to look at four companies that have generated headlines in recent months. All four are well on the way to establishing themselves as players in the cannabis sector, but each one is following a separate path to success. Aurora Cannabis, Inc. (TSE:ACB)Aurora is staking its future on size, positioning itself as the world’s largest supplier of cannabis products to the medical market. And large is definitely the right word – Aurora’s current production stands at more than 25 metric tons per quarter, and is on track to exceed 600 tons annually by the end of 2020.The company’s scale has brought Aurora both benefits and costs. On the positive side, Aurora gains economies of scale. High-volume production provides a higher revenue stream, and open doors to bulk customers that are unavailable to smaller producers. This was clear in last month’s quarterly report, which showed a 367% year-over-year gross revenue increase, and a 99% quarter-over-quarter increase in production. The cost to the company was clear, however. Aurora reported a loss of $158.4 million Canadian, coming out to 16 cents per share.The operating loss, despite the production and revenue increases, stems from the company’s heavy investments in increased acreage and growing facilities. Management expects that the benefits of those investment – in higher production and lower costs per unit sold – will outweigh the costs and begin generating positive earnings by Q4.Early last month, five-star analyst Martin Landry (Track Record & Ratings), GMP FirstEnergy’s expert on the consumer health sector, weighed in on Aurora, saying, “Data tracking dried flower inventory availability for online recreational cannabis stores in Ontario, Quebec and Alberta, or about 73% of the Canadian population, found that Aurora has been best performer with a more than 25% share of in-stock SKUs since the start of the year.” Landry expects that Aurora will become the industry leader, building on that strong presence. He gives the company a price target of $15 Canadian, suggesting an upside of 48%.Overall, Aurora gets a ‘Strong Buy’ from the analyst consensus, based on 6 buys and 1 hold given over the past three months. The company’s average price target, $14.33 Canadian, and current share price, $10.13 Canadian, give an upside potential of 41%.View TSE:ACB Price Target & Analyst Ratings Detail Canopy Growth (TSE:WEED)Like Aurora, Canopy is a giant in the cannabis industry. By market cap, it’s the largest company in the sector, and has the second highest production – a reversal of Aurora’s numbers. And while Aurora is positioning itself to supply the medical market, Canopy has put itself squarely in the recreational segment of the cannabis field. In a widely publicized move at the end of last year, Canopy was partially acquired by Constellation Brands (STZ), the alcohol giant that owns two of Mexico’s largest beer brands.Canopy is also investing heavily in future production and the American market; the company is scheduled to approve an acquisition deal with US grower Acreage on June 19. The move, in which Canopy will put down $300 million for rights to finish the purchase “if and when” the US Federal government legalizes marijuana nationally. The move will give Canopy an ‘in’ for the US market, when restrictions on interstate trade are lifted.Looking at the two acquisition plans together, it’s clear that Canopy is eyeing the American recreational cannabis market. Even if the Federal government does not legalize marijuana any time soon (putting the Acreage deal on hold), Canopy’s partnership with Constellation Brands gives it a chance to develop cannabis infused beverages with a line on distribution networks in the US and worldwide.Writing from Alliance Global Partners, Aaron Grey (Track Record & Ratings) points out that Canopy’s Acreage deal, should it be approved, will position Canopy to take the lead in the US cannabis market, the world’s largest. He also points out the importance of the company’s profitable base in Canada’s recreational market: “[While we do] not foresee Canopy being profitable until FY21, expect the company to be profitable in the Canadian cannabis market as it continues with its international expansion.”Canopy’s size – in production and market cap – along with its profitable Canadian base business, underlies its "Moderate Buy’ analyst consensus rating. In the last three months, Canopy has received 6 buy ratings and 4 holds. WEED shares sell in Toronto for $55 Canadian; the average price target of $80 Canadian gives the stock a 45% upside potential.View TSE:WEED Price Target & Analyst Ratings Detail Charlotte’s Web Holdings (TSE:CWEB)The US state of Colorado has been a leader in the cannabis legalization movement, making it a natural home for US cannabis companies. Based in the city of Boulder, Charlotte’s Web recently up listed to the Toronto Stock Exchange, making it the first American cannabis company to do so. The company’s niche – hemp-based cannabidiol (CBD) extracts and products – while not fully legal under US Federal law, is more widely accepted at the state level than THC-derived cannabis products and can be sold online in the United States.CBD products, in both the consumer health and prescription markets, are growing increasing popular in the US. Charlotte’s Web has capitalized on that, and now has a presence in over 6,000 retail locations around the country, and is seeing increasing business online. In response to increasing demand, the company has ramped up its production capabilities, and is now growing on double its 2018 acreage. Management expects to produce in excess of 500 metric tons of hemp and hemp products this year, and predicts that revenue will double to $145 US.Charlotte Web’s greatest advantage, however, is not the popularity of its product or the increasing demand and production. Rather, it’s that the company is already profitable. After its IPO in 2018, the company generated earnings of 16 cents per share, and that number is expected to hit 33 cents this year and 75 cents in 2020.Jason Zandberg (Track Record & Ratings), five-star analyst with PI Financial, notes all of this in his recent review of CWEB stock. He points out, “CWEB has now shipped first orders to three national brand supermarket/grocery and drugstore retailers in select states, with shipments to a fourth commencing post-Q1. Also, e-commerce sales, which accounted for 49 per cent of total sales in the quarter, grew by 60 per cent year-over-year…”Zandberg sees CWEB generating 2019 revenues of $142.9 million, in line with the company’s guidance, and predicts that 2020 revenues will exceed $300 million. Building on these upbeat forecasts, he sets a price target of $30 Canadian for CWEB shares, suggesting an upside of 102%. His target for the stock is only slightly more optimistic than the conventional wisdom. The average price target on CWEB in Toronto is $29.50 Canadian; with a share price of $14, this gives the stock a 98% potential upside. The analyst consensus, a ‘Moderate Buy,’ is based on 2 buy ratings.View TSE:CWEB Price Target & Analyst Ratings Detail GW Pharmaceuticals, Plc. GWPHThe last article in today’s look at cannabis market leaders is also an early entrant to the field, and the only one to trade on the US markets. GW Pharma formed in the UK, in 1998, to conduct research into medical uses of both CBD and THC, the main active compounds in cannabis. Last year, the company received approval for its cannabis-based epilepsy drug, Epidiolex. Sativex, a treatment for symptoms of MS, has been on the markets since 2010.GW’s niche in the cannabis world is a bit unique. It’s not going for the recreational market at all, nor is it interested in the consumer health sector. It is a traditional pharmaceutical company, that saw the potential for cannabis-based prescription medications early on, and is now reaping the benefit of that very early entrance to the field.In its last quarterly report, GW publicized the results of the Epidiolex launch. Writing from Piper Jaffray, Danielle Brill (Track Record & Ratings) said, “GWPH continues to deliver. We think the growth trajectory will continue over the coming quarters given expected EU launch, ongoing dose-titrations, increasing penetration into adult population, transition of remaining expanded access program patients to commercial product, and expansion into new indications.” Her $210 price target on the stock (a 13% boost from her previous target), suggests an upside of 22%.Paul Matteis (Track Record & Ratings), of Stifel, also sees a bright future for the company. Writing of the Epidiolex approval and initial sales, he points out both the forecast-beating profits and management’s prudent words of caution: “GW reported an extremely strong 1Q with $33.5M in Epidiolex sales, consensus was ~$16MM. While the 600%+ q/q rev growth rate was spectacular, management was careful to remind investors that the quarter benefited from ~5 months of pent-up demand and patient-finding efforts.” Matteis gives GWPH a ‘Buy’ rating with a target of $227, or a32% upside from current levels.GW Pharmaceuticals has a unanimous analyst consensus of ‘Strong Buy,’ based on 10 buy ratings. The stock is trading for $170, and the average price target of $219 gives an upside of 28%.View GWPH Price Target & Analyst Ratings DetailFind out more about these four leading cannabis stocks, and many more, with TipRanks’ Stock Comparison Tool.Canopy, Charlotte's Web, Aurora, and GW Pharma in the Stock Comparison Tool

  • GW Pharmaceuticals (GWPH) Should Find a Place in Your Portfolio
    SmarterAnalystlast month

    GW Pharmaceuticals (GWPH) Should Find a Place in Your Portfolio

    June has been one roller coaster ride for cannabis stocks. First, the FDA reported that CBD be treated like a drug causing cannabis stocks to decline, then a slurry of upgrades caused some cannabis stocks to soar and now the whole industry is rebounding with overall good investor sentiment.Honestly, no surprises for such a volatile industry. This volatility, surprising last-minute news and enormous swings are nothing new for cannabis stocks. Although one stock was particularly interesting. When the FDA reported its ‘findings’ for CBD, GW Pharmaceuticals (GWPH) seemed to explode.From a technical standpoint, GWPH is a very interesting stock. Unlike most of the industry, GWPH is trending positively beyond any normal cannabis stock consolidation. In fact, the stock is looking more like an incredibly bullish long-term buy. Why is GW Pharmaceuticals so interesting? First of all, after the FDA’s ruling on CBD, GWPH stock jumped. Why? Because the company owns one of the only CBD products approved by the FDA for treatment of both childhood-onset forms of epilepsy. The drug itself is called Epidiolex and you’ll be hearing a lot about it in the weeks to come. Having close ties with the FDA is a really good asset to have. Although letting companies have free reign over CBD would be good for everyone, the government is still in charge of consumer safety. Federal bodies like the FDA won’t just back down from controlling weed products or CBD. It’s still going to be a tax, health and legal issue. So don’t expect the FDA to just wipe its hands clean and forgive or forget CBD products.Another important factor is that GW Pharmaceuticals is neither a Canadian or American company. It’s located and licensed in United Kingdom. Why is important? Because the European market is an incredibly valuable future marketplace for many big producers including Canopy and Aurora. Having a stationed and licensed cannabis company in any European country makes it an incredibly valuable proposition for investors. Companies like GW Pharmaceuticals will build resistance within their governments to prevent larger cannabis companies from simply setting up shop in their markets. Depending on how Brexit plays out, the final deal with the EU might either boost GW Pharmaceuticals or restrict its access to Europe. But most likely, some type of free trade agreement will exist between EU states and United Kingdom since trade is such an incredibly valuable part of Europe. Additional, European sentiment towards pot is positive. Most European countries are fairly libral when it comes to legalization and taxation of weed. Remember, pot was legal in parts or Europe way before North America.For investors, GW Pharmaceuticals looks like a great stock. The company itself reported better than expected sales for Epidiolex and announced recently positive results from its phase 3 study of the drug treating another rare type of epilepsy. And overall its been on a run and consolidating in a tight range upwards. It’s also a great stock to diversify away from strictly American and Canadian cannabis market. Looks like a great investment for the future of global cannabis.Analysts seem to agree. The cannabis player stands as a 'Strong Buy' name among Wall Street analysts, according to TipRanks. In the last three months, GWPH has won 10 bullish 'buy' recommendations. With a return potential of nearly 23%, the stock's consensus price target lands at $219.56.To read more on the nitty gritty of what’s going on in the rising cannabis industry, click here. Read more on GWPH: * Medicinal Cannabis Stock GW Pharmaceuticals Could Run Much Higher Over Time * Analysts Have Chosen: GWPH, APHA and CGC Are Top Cannabis Stock Picks More recent articles from Smarter Analyst: * Curaleaf Helping to Put U.S. Cannabis Sector on the Map * Netflix’s (NFLX) Original Content Strategy Is Failing; The Stock Is Overvalued * Marijuana Stock KushCo (KSHB): Potential Catalysts Vs. Risks * Evercore Continues to Hold a Bullish View on Bank of America (BAC) Stock

  • The FDA Hearing on CBD Is Really Much Ado About Nothing
    Motley Foollast month

    The FDA Hearing on CBD Is Really Much Ado About Nothing

    No matter what the FDA decides with regard to cannabidiol as a food or beverage additive, it'll have little bearing on consumers or investors.

  • 3 Top Marijuana Stocks to Watch in June
    Motley Foollast month

    3 Top Marijuana Stocks to Watch in June

    With the industry possibly cooling off, here are the names to remember.

  • Here's What Last Week's FDA CBD Hearing Really Means for Cannabis Stocks
    Motley Fool2 months ago

    Here's What Last Week's FDA CBD Hearing Really Means for Cannabis Stocks

    The bottom line: a whole lot of uncertainty.

  • Investing in Marijuana Stocks: Everything You Need to Know
    Motley Fool2 months ago

    Investing in Marijuana Stocks: Everything You Need to Know

    Should you put your hard-earned money into these stocks? We detail the investment opportunities, the risks, and regulations in the cannabis space.

  • 3 ‘Strong Buy’ Cannabis Biotech Stocks To Know Now
    TipRanks2 months ago

    3 ‘Strong Buy’ Cannabis Biotech Stocks To Know Now

    If you are looking to invest in cannabis stocks, you may want to take a closer look at cannabis biotechs in particular. Several cannabis biotech firms are generating significant Street support- and for good reason as you will see below. To pinpoint the most compelling cannabis biotech stocks out there, we used TipRanks' data to pull up relevant biotechs with a 'Strong Buy' Street consensus. That's based on all the ratings received from analysts over the last three months. In fact, all these three stocks actually score 100% Street support- so no hold or sell ratings here. Let's take a closer look now at which 3 stocks make the grade, and why: GW Pharmaceuticals (GWPH – Research Report)British-based biopharma GWPH is one of the more well-known cannabis biotech stocks. Shares have put on a remarkable sprint for the beginning of 2019. Year-to-date we are now looking at gains of 88%. And the company’s recent earnings report indicates that plenty of growth lies ahead. In June 2018, the company’s lead cannabinoid drug Epidiolex received FDA approval for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome. Following DEA re-scheduling, Epidiolex was launched on November 1.So far the launch has proved a remarkable success. For the first quarter, GW reported $33.5MM in Epidiolex revenue during its first full quarter on the market, well ahead of consensus ($15.9MM). But even more importantly, the company also revealed positive trial data for tuberous sclerosis complex (TSC). Specifically, GW announced that Epidiolex's Phase III trial in patients with seizures associated with tuberous sclerosis complex (TSC) met its primary endpoint with a high degree of statistical significance.The primary endpoint was the percent change from baseline in seizure frequency during the treatment period. At baseline, enrolled patients (average age of 14 years old) experienced a median of 57 seizures per month. After 16 weeks of treatment, patients in the 25 mg/kg/day cohort experienced an impressive 48.6% reduction in seizures relative to baseline.“1Q Snapshot \- A Strong Launch and Positive TSC Data Rolled Into a Joint Announcement for a Double Dose of Good News” cheered JP Morgan’s Cory Kasimov following the report. The analyst continued: “We’re not sure how GWPH’s 1Q19 report could have gone much better with Epidiolex doubling consensus in its first full quarter of sales… only to be one-upped by concurrent positive Phase 3 data in TSC.”As a result he believes Epidiolex is on track to come in north of $150M in its first full year, easily exceeding Street expectations. “The bottom line is that estimates need to come up, perhaps meaningfully. Furthermore, with another positive – and clean – phase 3 dataset in hand, there could be upward bias to longer term off label epilepsy sales, which offers a major upside lever in our model” concludes Kasimov. He reiterated his buy rating while ramping up his price target from $180 to $215. Unsurprisingly, he wasn’t the only analyst singing GWPH’s praises. “Based on Epidiolex's trajectory and the positive TSC data today we are increasing our DCF-based price target from $175 to $200. We continue to think that GW is undervalued” commented Cowen & Co’s Phil Nadeau. At the same time Oppenheimer’s Esther Rajavelu took a step further by upgrading GWPH from Hold to Buy. She also upped her price target from $164 to a Street-high $234 (27% upside). “While we await detailed data that may be shared at a medical conference, we update our probability of approval of the sNDA [supplemental new drug application] for TSC to 87% from 41% (filing expected in 4Q)” she explained. Overall GWPH has a very bullish outlook from the Street, with ten analysts publishing recent buy ratings on the stock. Their average analyst price target stands at $220- indicating upside potential of 20%. View GWPH Price Target & Analyst Ratings Detail Zynerba Pharmaceuticals Inc (ZYNE – Research Report)Zynerba is developing next-generation cannabinoid gels to help treat patients affected by rare neuropsychiatric conditions. The company is generating a significant buzz, with shares exploding over 340% year-to-date! So what’s behind the stock’s meteoric rise?Its lead drug candidate Zygel is a unique permeation-enhanced CBD transdermal gel. By delivering drugs through the skin and directly into the circulatory system, Zygel offers several advantages over oral medication. Most notably, transdermal delivery results in fewer gastrointestinal side effects, and avoidance of first-pass liver metabolism. This potentially enables lower dosage levels of active pharmaceutical ingredients and rapid, reliable absorption. Encouragingly, Zynerba announced earlier this month that the FDA has granted a Fast Track designation on Zygel for the treatment of behavioral problems associated with Fragile X syndrome (FXS). “With this designation, the company gains easier access to the FDA throughout the development process and most importantly, in our view, eligibility for Priority Review, which shortens the review time to six months” explains Ladenburg’s Michael Higgins. He anticipates Zygel’s NDA (new drug application filing) will take place in 1H20, leading to approval in 2H20. And with an eye on the future, Higgins reiterates his buy rating on ZYNE with a $26 price target (97% upside potential). While data since the summer of 2018 has been light, multiple major data readouts are comping up near-term- generating the recent rally in prices. “We continue to believe the stock could still double from its current level, driven by a data-rich 2H’19” the analyst tells investors. Upcoming data readouts include Phase 2 data from BELIEVE 1, evaluating Zygel’s anti-epileptic activity, and data from the FXS pivotal CONNECT-FX trail. “Given the unprecedented, profound and sustained benefits across multiple behavioral problems in the open-label Phase 2 (FAB-C), plus Zygel’s good tolerability, we again expect this trial to be successful” writes Higgins. Plus the catalysts should continue into 1H20 when data is expected for two new indications (autism spectrum disorder (ASD) and 22q11.2 deletion syndrome). Analysts are clearly feeling the heat- this is a stock with five recent back-to-back buy ratings and an average analyst price target of $23 (79% upside potential). View ZYNE Price Target & Analyst Ratings Detail Cara Therapeutics Inc (CARA – Research Report)Cara Therapeutics is a biotech focusing on developing products for better pruritus (i.e. severe itching- one of the most common dermatological complaints) and pain management. Right now, all eyes are squarely set on the imminent US Phase 3 data for IV Korsuva. This is Cara’s novel kappa opioid receptor agonist to treat chronic kidney disease-associated pruritus (CKD-aP) in hemodialysis patients- where there is currently no effective treatment and minimal competitive development.Indeed top-rated Cantor Fitzgerald analyst Charles Duncan has just hosted a call with a key opinion leader (KOL) to discuss the outlook for Korsuva. In this case the KOL is a physician with expertise in chronic kidney disease associated pruritus (CKD-aP), making his insights particularly valuable. Overall, the KOL stated that, in his 25 years as a practicing nephrologist, he has seen little in drug development move the needle in CKD-aP (except the P2 data from KORSUVA), underscoring the need for new medications.“As a result of this recent due diligence, we have enhanced conviction about the P3 study readouts and potential for KORSUVA to usher-in a paradigm shift and a new SoC [standard of care] for this high-burden symptom of disease” Duncan concluded. He expects the data readout to come early June, and is upbeat about the drug's prospects. “We remain confident in positive results based on statistically significant Phase 2b results with much lower powering and shorter treatment duration” the analyst tells investors. Meanwhile, the second global Phase 3, KALM-2, is enrolling and management expects data in “2H19” (i.e. around 4Q). "Assuming KALM-1 is positive, we’ll also be optimistic for KALM-2", says the analyst. He reiterated his buy rating with a $27 price target, writing ‘Now is the time to scratch the itch.’ Given the stock is currently only trading at $18, the price target translates into sizable upside potential of over 50%. Bear in mind shares are already soaring 39% year-to-date. As we can see here, that's on top of six recent buy ratings from the Street:View CARA Price Target & Analyst Ratings Detail Enjoy Research Reports on the Stocks in this Article:Cara Therapeutics Inc (CARA) Research ReportGW Pharmaceuticals (GWPH) Research ReportZynerba Pharmaceuticals Inc (ZYNE) Research Report

  • Comparing GW Pharmaceuticals’ Returns to Peers
    Market Realist2 months ago

    Comparing GW Pharmaceuticals’ Returns to Peers

    Comparing GW Pharmaceuticals’ Returns to PeersGW PharmaceuticalsGW Pharmaceuticals (GWHP) is primarily into the development of cannabis-derived prescription medicines. Liquid cannabidiol (or CBD) is the leading product in the company’s

  • GW Pharmaceuticals (GWPH) Stock Could Run Much Higher Over Time
    SmarterAnalyst2 months ago

    GW Pharmaceuticals (GWPH) Stock Could Run Much Higher Over Time

    GW Pharmaceuticals (GWPH) has recently bounced after a solid earnings report. It also announced its phase-3 trial concerning its Epidiolex oral medicine, received positive results.The combination of the earnings beat and forward movement of Epidiolex, provide catalysts that should continue to drive GWPH stock price higher.The CatalystsRevenue in the latest reporting period ended March 31, 2019 came in at $39.2 million, far above the $3 million in revenue generated in the same reporting period of 2018, beating estimates by $23.33 million.Earnings for the quarter improved to a loss of $50.1 million, against the loss of $69.5 million year-over-year. Earnings per share was $-0.14, beating estimates by $0.07.Cash and cash equivalents fell from $591.5 million at the end of calendar year 2018, to $521.7 million at the end of the quarter.The second catalyst was the report of the company reaching another "primary efficacy measure with both EPIDIOLEX doses as compared to placebo." That was the "consecutive positive Phase 3 pivotal trial for EPIDIOLEX." The company is expected to file an sNDA in the fourth quarter of 2019.Net sales of Epidiolex in the quarter was $33.5 million, accounting for the majority of the revenue.Things to Consider for Current ShareholdersThere are a couple of important things to take into consideration with existing shareholders, including its share price and whether or not it can break out from its recent new highs.With its improvement with revenue and earnings, and its consistent positive news about Epidiolex, it would take a significant negative catalyst to reverse the sentiment in regard to the company, which suggests it may still have a lot of upward trajectory left.For that reason, unless shareholders want to take some profits off the table, it appears to be a low-risk play to maintain a position because the share price has a lot more room to run.Thoughts on Investors Looking to Take a Position in GWPHInvestors wanting to move quickly in and out of the stock would do better to wait to see if it drops below the recent breakout line before taking a position. Being a volatile stock, it would be best to wait for it to pull back and play the bounce if it comes.Spending is of particular concern, as the company projected operating expenses in a range of $395 million to $425 million for full-year 2019. It's almost certain that sales won't be able to cover those costs.The good news is at the end of the quarter the company had $521.7 million in cash, along with an additional $105 million it received from the sale of a review voucher in April.Even with rapidly growing revenue, increasing insurance coverage of the treatment, and its success in clinical trials, the company will continue to struggle to generate a profit in the near term. For that reason, investors wanting a stronger risk/reward metric, will probably stay away until the company shows it can generate a profit.One significant event that could be a powerful catalyst for GW Pharmaceuticals is if an European advisory committee gives approval this quarter for Epidiolex. If that's how it's plays out, patients with LGS and Dravet syndrome will have access to the treatment, providing a major boost in sales, and a  quicker path to profitability; there already is pricing and reimbursement in place in key European markets Germany and France.With all the expansion and additional costs, management believes the $521.7 million in cash and cash equivalents should be enough to cover the next 12 months.ConclusionGW Pharmaceuticals continues to prove it has a lot going for it, with it continuing to grow Epidiolex revenue, expand its footprint, and lowering costs while it's doing so.Both revenue, earnings and Epidiolex are all moving in the right direction together, and that provides a bullish scenario that should continue to support and push up the share price of the company, even though I suspect there will be a correction in the near future after its share price has almost doubled so far in 2019.For long-term holders, it will be a chance to add more to your position and lower your cost basis.As the company stands today, I think the long-term opportunity outweighs the short-term, because of the price support and accompanying contracting price range the company will trade in on a daily basis when it's volatile.If you believe in GW and are in it for the long haul, there's really not much to do but hold on to your shares and ride the upward wave. I would be patient if you want to add to your position, waiting for the inevitable pullback.To read more on the nitty gritty of what’s going on in the rising cannabis industry, click here. Read more on GWPH: * Analysts Have Chosen: GWPH, APHA and CGC Are Top Cannabis Stock Picks * GW Pharmaceuticals (GWPH): A “Blue Chip” Cannabis Stock to Watch More recent articles from Smarter Analyst: * Charlotte's Web Stock Is Still One of the Best Cannabis Stock Plays * Why Cresco Labs Stock Deserves More Respect Than It’s Given * Cannabis Stock Cresco Labs Should Rise – Here's Why * Aurora Cannabis (ACB) Stock Set to See Big Gains, Says Analyst

  • The Smartest People on Wall Street Are Buying These 3 Stocks -- Should You Follow?
    Motley Fool2 months ago

    The Smartest People on Wall Street Are Buying These 3 Stocks -- Should You Follow?

    Why are billionaire investors betting on stocks like Disney and GW Pharmaceuticals?

  • Benzinga2 months ago

    The Week In Cannabis: A&F Tries CBD, GW Pharma Soars On Results, Denver Decriminalizes Mushrooms

    The cannabis world had an unlikely protagonist: magic mushrooms . After a popular vote, the city of Denver, Colorado, known as a legal cannabis trailblazer, approved a ballot measure to decriminalize psychedelic ...